GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291 according to findings discussed at the European Lun
GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291 according to findings discussed at the European Lung Cancer Conference. Pasi Jänne MD PhD from the Dana-Farber Cancer Institute in Boston MA, Director of the Lowe Center for Thoracic Oncology and Professor of Medicine at Harvard Medical School, gave Oncology Times reporter Peter Goodwin the latest details about the clinical potential of this therapy.